Category: Pα+ - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

Post published:September 5, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Post published:September 3, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

Post published:August 28, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Post published:August 25, 2025
Post category:Analysis News Pα+

Read more about the article Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

Post published:August 25, 2025
Post category:Analysis News Pα+

Read more about the article July 2025 Psychedelic Patent Update

July 2025 Psychedelic Patent Update

Post published:August 22, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

Post published:August 18, 2025
Post category:Analysis News Pα+

Read more about the article One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Post published:August 15, 2025
Post category:Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

Post published:August 8, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

Post published:August 5, 2025
Post category:Analysis Interviews News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.